Waklert (armodafinil 150mg, Sun Pharma)

Waklert is the brand name under which Sun Pharmaceutical Industries sells armodafinil, here as a 150mg tablet. The active substance is the same as in unbranded armodafinil: the R-enantiomer of modafinil, the half of the racemate that the body clears markedly more slowly than the other. What sits in the blister is not a different molecule, it is a different origin. Sun Pharma is one of India's largest pharmaceutical manufacturers and also makes Modalert, one of the country's best known modafinil brands.

Clinically, armodafinil (sold in the US as Nuvigil) is approved for excessive daytime sleepiness in narcolepsy, treated obstructive sleep apnea and shift work disorder. It belongs to the eugeroics, the wakefulness promoters. Structurally it is not an amphetamine. The pharmacokinetic rule of thumb: 150mg armodafinil delivers roughly the total exposure of 200mg modafinil, because the fast-clearing S-half is missing. The 150mg tablet is therefore the standard strength, not a reduced dose.

This information is for research and educational purposes only. No medical advice.

Armodafinil inhibits the dopamine transporter (DAT), slowing dopamine reuptake into the neuron so that more dopamine remains in the synapse. Unlike amphetamines it does not force the cell to release dopamine. That difference explains the calmer character: drive is not turned up, tiredness is taken away. In binding studies the R-enantiomer is the part of the racemate that sits more tightly on the transporter, so Waklert and modafinil work through the same lever.

On top of that come indirect effects on the wake systems of the hypothalamus. Orexin and histamine neurons are activated, cortical catecholamine tone rises, GABA falls. Those are the circuits that pace the sleep-wake cycle, not the general reward and drive systems. The mechanism is still not fully resolved, but the outline applies equally to the racemate and the R-enantiomer.

In practice: Waklert does not make you euphoric and, in the research setting, not demonstrably smarter either; it keeps you awake. What it cannot do is replace sleep. Cover the deficit for days and the bill arrives the following night.

Between Waklert and a generic armodafinil 150mg there is no pharmacological difference that the literature could support. Same active substance, same strength, the same registration trials behind it. We are not aware of any study comparing Waklert against other armodafinil products. Anyone expecting a stronger effect from the brand is expecting something the data do not provide.

The difference lies in the origin. Sun Pharma is a large manufacturer with its own brand and its own blister. For many that is exactly the reason to stay with the brand: a named maker standing behind the batch. That is a practical argument, not a pharmacological one. If you only want the substance, generic armodafinil serves you just as well; the lexicon entry on armodafinil covers the same compound without the brand focus.

The gap to modafinil, on the other hand, is real and measurable. It sits not at the peak but in the second half of the day. More on that in the next section.

Taken on an empty stomach, armodafinil peaks after about 2 hours. A meal barely changes total absorption but pushes the peak back by 2 to 4 hours. That shifts the whole course of action into the afternoon (prescribing information). The terminal half-life is around 15 hours, the decline is single-phase, steady state is reached after about 7 days of daily dosing and then sits 1.8 times above a single dose. Kinetics are linear between 50 and 400mg.

Darwish and colleagues (Clinical Drug Investigation 2009) drew the comparison with the racemate in healthy men at steady state, dose-normalized to 200mg per day after seven days of morning dosing. Armodafinil plasma levels ran higher than modafinil's across the day, most clearly late in the day: between 3pm and 7pm after an 8am dose they were 44 percent higher on average, with 28 percent less fluctuation across the dosing interval. The authors note that this difference cannot simply be made up with more modafinil without reopening the safety question.

For you that means two things. First: dose early or not at all, a midday dose carries deep into the night. Second: take it fasted if you want the effect on time, because with breakfast the peak drifts into the afternoon. In older adults clearance is slower and the prescribing information advises lower doses, as it does in severe hepatic impairment.

The strongest evidence is in shift work. Czeisler and colleagues (Mayo Clinic Proceedings 2009) randomized 254 night shift workers with chronic shift work disorder at 42 centers to 150mg armodafinil or placebo, taken 30 to 60 minutes before each night shift for 12 weeks. Mean sleep latency during the night shift rose from 2.3 to 5.3 minutes on armodafinil, versus only 2.4 to 2.8 on placebo. Memory and attention improved on standardized tests. Daytime sleep was unchanged on polysomnography.

Drake and colleagues (Sleep 2014) looked at the practical side of the same question: 20 night workers with shift work disorder drove a simulator after 150mg armodafinil or placebo at 11:45pm in a crossover design. Lane keeping and off-road deviations improved significantly, objective sleep latency rose from 3.7 to 9.7 minutes. The effects lasted up to 9.5 hours after dosing, through the morning commute home.

In narcolepsy, Harsh and colleagues (Current Medical Research and Opinion 2006) compared 150mg, 250mg and placebo in 196 patients over 12 weeks. Both doses lengthened wakefulness on the Maintenance of Wakefulness Test (plus 1.3 and plus 2.6 minutes against minus 1.9 on placebo) and improved memory, attention and fatigue. In treated sleep apnea, Roth and colleagues (Clinical Therapeutics 2006) found the same pattern in 395 patients on CPAP: more wakefulness across morning and afternoon, 72 versus 37 percent clinically improved, no disruption of night sleep on polysomnography.

What is missing is evidence of cognitive enhancement in rested healthy people. The healthy-volunteer studies of armodafinil were almost all run under sleep deprivation. For the racemate, meta-analyses show only a small effect, as described in the modafinil entry. Waklert is well documented against tiredness and weakly documented as a thinking aid.

Armodafinil induces CYP3A4/5 and inhibits CYP2C19 (prescribing information). The first direction lowers the levels of substances cleared through CYP3A4: hormonal contraceptives, cyclosporine, midazolam, triazolam. For contraception that means reliability is reduced during use and for about one month after stopping. An additional method is recommended. It is the most overlooked point of the whole substance class.

The second direction raises the levels of CYP2C19 substrates: phenytoin, diazepam, propranolol, omeprazole, clomipramine. With warfarin the prescribing information advises more frequent INR checks, with MAO inhibitors caution. Because enzyme induction takes days to build up and to fade, these effects are not limited to the day of dosing. Anyone taking one of the substances named should clear the question with a doctor before adding armodafinil.

• Serious skin reactions: rare, but the gravest warning in the prescribing information. Rash requiring hospitalization, up to Stevens-Johnson syndrome and toxic epidermal necrolysis, is documented for armodafinil and modafinil, along with DRESS (hypersensitivity with organ involvement) and angioedema. In the pooled registration trials rash occurred in 1 percent on 150mg and 4 percent on 250mg. Any new rash is a reason to stop; blistering or mucous membrane involvement is a case for immediate medical assessment.
• Headache: by far the most common, 17 percent versus 9 on placebo, dose-dependent (14 percent on 150mg, 23 on 250mg). The most frequent reason for discontinuation.
• Nausea, dizziness, dry mouth, diarrhea: 7, 5, 4 and 4 percent in the trials, mostly mild and transient.
• Insomnia: 5 percent versus 1 on placebo; with armodafinil's flat decline it is almost always a question of timing.
• Mental state: anxiety in 4 percent, plus nervousness, agitation and depressed mood. With a history of psychosis, depression or mania the prescribing information calls for particular caution. If psychiatric symptoms appear, it calls for stopping.
• Circulation: in the registration trials blood pressure rose by 1.2 to 4.3 mmHg on average and pulse by 0.9 to 3.5 beats per minute. Closer monitoring is advised with known cardiovascular disease.
• Discontinuations: 7 percent on armodafinil versus 4 on placebo left the trials because of adverse reactions.
• Abuse potential: lower than with amphetamines, but present. Armodafinil is a Schedule IV controlled substance in the US. Cases of abuse with euphoria and escalating doses have been reported.
• Pregnancy: harmful to the fetus in animal studies; the prescribing information points to a dedicated pregnancy exposure registry.

Store dry, at room temperature and protected from light, ideally in the blister until you need a tablet. Use split halves within the next few days rather than leaving them open for weeks. Keep out of reach of children.